Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.
2.

18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases.

Braun JJ, Kessler R, Constantinesco A, Imperiale A.

Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1537-43. doi: 10.1007/s00259-008-0770-9. Review.

PMID:
18418595
3.

Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis.

Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, Miura M, Sakaue S, Tamaki N, Nishimura M.

Eur J Nucl Med Mol Imaging. 2008 May;35(5):933-41.

PMID:
18084757
4.

Indeterminate pulmonary nodules on CT images in breast cancer patient: the additional value of 18F-FDG PET/CT.

Evangelista L, Panunzio A, Cervino AR, Vinante L, Al-Nahhas A, Rubello D, Muzzio PC, Polverosi R.

J Med Imaging Radiat Oncol. 2012 Aug;56(4):417-24. doi: 10.1111/j.1754-9485.2012.02408.x.

PMID:
22883649
5.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.

Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa.

PMID:
19687736
6.

Imaging in sinonasal sarcoidosis: CT, MRI, 67Gallium scintigraphy and 18F-FDG PET/CT features.

Braun JJ, Imperiale A, Riehm S, Veillon F.

J Neuroradiol. 2010 Jul;37(3):172-81. doi: 10.1016/j.neurad.2009.09.001.

7.

18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.

Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF, Wang HM, Wong HF.

J Nucl Med. 2005 Jul;46(7):1136-43.

8.

The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods.

Moon SH, Cho SK, Kim WS, Kim SJ, Chan Ahn Y, Choe YS, Lee KH, Kim BT, Choi JY.

J Nucl Med. 2013 Jul;54(7):1039-44. doi: 10.2967/jnumed.112.113399.

9.

18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence.

Ito K, Yokoyama J, Kubota K, Morooka M, Shiibashi M, Matsuda H.

Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1318-27. doi: 10.1007/s00259-010-1400-x.

PMID:
20306040
10.

Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.

Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, Kondo T, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H.

BMC Cancer. 2008 Jun 9;8:165. doi: 10.1186/1471-2407-8-165.

11.

18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.

Koolen BB, Vrancken Peeters MJ, Aukema TS, Vogel WV, Oldenburg HS, van der Hage JA, Hoefnagel CA, Stokkel MP, Loo CE, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.

Breast Cancer Res Treat. 2012 Jan;131(1):117-26. doi: 10.1007/s10549-011-1767-9.

PMID:
21935602
12.

Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up?

Abgral R, Querellou S, Potard G, Le Roux PY, Le Duc-Pennec A, Marianovski R, Pradier O, Bizais Y, Kraeber-Bodéré F, Salaun PY.

J Nucl Med. 2009 Jan;50(1):24-9. doi: 10.2967/jnumed.108.055806.

13.

Delayed response assessment with FDG-PET-CT following (chemo) radiotherapy for locally advanced head and neck squamous cell carcinoma.

Prestwich RJ, Subesinghe M, Gilbert A, Chowdhury FU, Sen M, Scarsbrook AF.

Clin Radiol. 2012 Oct;67(10):966-75. doi: 10.1016/j.crad.2012.02.016.

PMID:
22595082
14.
15.

Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer.

Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, Kang SB.

Eur J Radiol. 2012 Aug;81(8):e817-22. doi: 10.1016/j.ejrad.2012.02.015.

PMID:
22595504
16.

Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.

Li M, Wu N, Liu Y, Zheng R, Liang Y, Zhang W, Zhao P.

Eur J Radiol. 2012 Aug;81(8):1886-90. doi: 10.1016/j.ejrad.2011.03.074.

PMID:
21511421
17.

Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.

Messa C, Ceresoli GL, Rizzo G, Artioli D, Cattaneo M, Castellone P, Gregorc V, Picchio M, Landoni C, Fazio F.

Q J Nucl Med Mol Imaging. 2005 Sep;49(3):259-66.

18.

Comparison of 18F-FDG positron emission tomography/computed tomography and computed tomography in patients with already-treated breast cancer: diagnostic and prognostic implications.

Evangelista L, Baretta Z, Vinante L, Bezzon E, De Carolis V, Cervino AR, Gregianin M, Ghiotto C, Saladini G, Pomerri F, Muzzio PC.

Q J Nucl Med Mol Imaging. 2012 Aug;56(4):375-84.

PMID:
23013667
19.

Prosthetic vascular graft infection: the role of 18F-FDG PET/CT.

Keidar Z, Engel A, Hoffman A, Israel O, Nitecki S.

J Nucl Med. 2007 Aug;48(8):1230-6.

20.

The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.

Hsieh HJ, Lin SH, Lin KH, Lee CY, Chang CP, Wang SJ.

Ann Nucl Med. 2008 Jul;22(6):533-8. doi: 10.1007/s12149-007-0142-8.

PMID:
18670862
Items per page

Supplemental Content

Support Center